Navigation Links
Neurocrine Biosciences Reports Third Quarter 2008 Results
Date:10/28/2008

istrative expenses is primarily due to cost savings related to recent restructurings.

The Company's balance sheet on September 30, 2008 reflected total assets of $207.7 million, including cash and investments of $118.2 million compared with balances at December 31, 2007 of $276.7 million and $179.4 million, respectively. The Company expects to end 2008 with approximately $100 million in cash and investments.

"We are pleased with the progress of our GnRH program, especially the recent positive results of our 603 study where once a day elagolix showed profound efficacy with minimal impact on bone mineral density. We are also nearing completion of the final preclinical studies of urocortin 2 to allow for long-term Phase II clinical studies and our scientists have just recently identified a clinical candidate from our VMAT2 development program for movement disorders," said Kevin Gorman, Chief Executive Officer and President of Neurocrine Biosciences. "While we are making great strides in advancing our pipeline, we continue to prioritize expenditures and diligently manage our cash burn."

R & D Pipeline Update

Neurocrine's clinical development group and corporate partners have five programs in clinical development. Neurocrine scientists continue to supply Neurocrine's pipeline to meet the Company-wide goal of bringing one new compound into development each year.

Elagolix for Endometriosis

The Company recently announced the positive safety and efficacy results from the completed 6-month treatment phase of its Phase IIb clinical trial (PETAL Study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix.

The primary endpoint, percent change from baseline in mean bone mineral density (BMD) demonstrated elagolix did not induce significant bone loss over the six month treatment period. Additionally, elagolix also met the secondary endpoints of improvement in endometrios
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
2. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
6. Neurocrine Biosciences Reports Second Quarter 2008 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
8. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013 Biotechnology industry pioneer Amgen ... software provider BlackLine Systems  and enterprise application software ... for a webinar next week entitled "No Account Left ... and SAP to Help Keep Its Account Reconciliations in Good ... The webinar, geared at finance, accounting, audit ...
(Date:6/19/2013)... June 19, 2013 India’s vast ... can potentially be worth up to a billion ... the Indian government is taking serious action to ... process. , This presentation will examine:, ... ,     Immediate and long term impacts , ...
(Date:6/19/2013)... Earth, MN (PRWEB) June 19, 2013 ... of abuse tests, today announced that it has received ... to market and sell its DrugCheck® NxStep Onsite ... allows use of the rapid screening device in near-patient ... Onsite Drug Screen Cup received Health Canada Class III ...
(Date:6/18/2013)... A million electric cars could be on roads across ... help of research by the United States Department of Energy, ... Professor Zhongwei Chen is part of a team led by ... to replace the expensive platinum catalysts in fuel cells. , ... cells in vehicles is the cost of the units. The ...
Breaking Biology Technology:Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 2Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 3Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 4Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3US and Canadian researchers drive towards cheaper fuel cells for electric cars 2
... The firm's shares shot up 40% this morning after it ... drug in the company's pipeline, has been found to extend ... ,Late last week, new data and a regulatory decision buttressed ... - news - people ) is developing ...
... (WMC), Valhalla, New York, has selected Verisis developed by ... Corporation , for its new Cardiology Image and Information Management ... George E. Reed Heart Center , one of the ... east coast. The system will also extend into the ...
... of streaming media was predominantly targeted toward consumer applications ... money hasn't followed. The focus on streaming media is ... that can improve productivity and the information experience. Just ... educational institutions are beginning to see the value of ...
Cached Biology Technology:Genentech's Winning Streak 2Genentech's Winning Streak 3NY Medical Center Selects Camtronics for Cardiovascular Image and Information Management 2
(Date:6/19/2013)... of the patients who received injections of steroids ... New England Compounding Center has found that some ... not experience a worsening of their symptoms and ... infection, especially among those individuals who received injections ... along with an editorial by UC Davis Assistant ...
(Date:6/19/2013)... 2013 A study published in the Journal ... report of an oral probiotic supplement significantly increasing circulating ... The lead author on the study, Mitchell Jones, MD, ... from the New York Academy of Sciences and the ... Prebiotics, and the Host Microbiome: The Science of ...
(Date:6/19/2013)... Flemish plant scientist Marc Van Montagu (born 1933) is ... the American scientists Mary-Dell Chilton and Robert T. Fraley. ... the US Secretary of State, John Kerry. The World ... agriculture" - gives the award annually to one or ... importance for the quality, quantity or availability of food. ...
Breaking Biology News(10 mins):Evolution of an outbreak: Complications from contaminated steroid injections 2Study shows probiotic Lactobacillus reuteri NCIMB 30242 significantly increased vitamin D levels 2World Food Prize goes to a Belgian for the first time: The scientist Marc Van Montagu 2World Food Prize goes to a Belgian for the first time: The scientist Marc Van Montagu 3World Food Prize goes to a Belgian for the first time: The scientist Marc Van Montagu 4
... A specific biological response to cellular stress may predict ... common, non-invasive form of pre-malignant breast cancer-- ductal carcinoma ... could potentially be used in a clinical setting to ... therapy when initially diagnosed with DCIS, according to a ...
... Using an extremely sensitive measurement technique, researchers at ... a lead-specific DNAzyme uses the lock and key reaction ... the same DNAzyme uses the induced fit reaction ... and key mechanism explains why this particular lead-specific DNAzyme ...
... a new vaccine be the key to stopping Alzheimers ... Research Foundation (OMRF) shows that immunization could offer a ... disease. OMRF scientists immunized Alzheimers mice with a ... disease-causing process. The mice who received the vaccination showed ...
Cached Biology News:Cell response to stress signals predicts tumors in women with common pre-breast cancer 2Cell response to stress signals predicts tumors in women with common pre-breast cancer 3The key to unlocking the secret of highly specific DNAzyme catalysis 2An Alzheimer's vaccine? 2An Alzheimer's vaccine? 3
Comp Dim: chamber diam. depth 20 2.8 mm chamber maximum volume 720 μL...
...
... A direct, simple approach ... the well surface of an ... anhydride maintains its integrity and ... under dry, room temperature conditions ...
... adsorption and clarification reagent; Ideal for ... of antibodies, proteins, nucleic acids, & ... cross-reactivity, and improves downstream processing; Utilizes ... non-ionic adsorbent supplied as a suspension ...
Biology Products: